Clinical Trials Browser

Phase 2 × OTHER × alectinib × Clear all

NCT02314481 2026-05-04

DARWINII

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT04116541 2026-04-24

MegaMOST

Phase 2 Recruiting

Neoplasm Metastasis

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Recruiting

Rare Tumor

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

Neoplasm Metastasis

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05015010 2024-08-09

ALNEO

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03779191 2023-07-06

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Phase 2 Completed

ALK Gene Rearrangement Positive

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms